Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738887) titled 'Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations' on July 27.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The Lymphoma Academic Research Organisation
Condition:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Intervention:
Drug: Ibrutinib Oral Tablet
Drug: Venetoclax Oral Tablet
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 31, 2026
Target Sample Size: 44
Countries o...